Nuvalent (NUVL) Current Assets (2020 - 2026)
Nuvalent's (NUVL) quarterly Current Assets came in at $1.3 billion in Q1 2026, up 20.37% YoY from $1.1 billion in Q1 2025, and down 6.07% on a QoQ basis from $1.4 billion in Q4 2025.
Analysis
Nuvalent (NUVL) Current Assets (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Current Assets data on file, last reported at $1.3 billion in Q1 2026.
- Quarterly Current Assets rose 20.37% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 20.37% YoY) and the FY2025 annual result came in at $1.4 billion, up 22.96% from the prior year.
- Current Assets declined to $1.3 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.4 billion in Q4 2025 to a low of $245.2 million in Q3 2022.
- A 5-year average of $749.3 million and a median of $699.5 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets fell 19.63% — and 2024, when it surged 181.03%.
- Tracing NUVL's Current Assets over 5 years: stood at $478.0 million in 2022, then jumped by 51.99% to $726.5 million in 2023, then jumped by 55.88% to $1.1 billion in 2024, then increased by 22.96% to $1.4 billion in 2025, then declined by 6.07% to $1.3 billion in 2026.
- The last three Current Assets figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $956.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 1.31 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31 Bn |
| Dec 31, 2025 | 1.39 Bn |
| Sep 30, 2025 | 956.95 Mn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 1.09 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 666.26 Mn |
| Mar 31, 2024 | 699.49 Mn |
| Dec 31, 2023 | 726.49 Mn |
| Sep 30, 2023 | 419.77 Mn |
| Jun 30, 2023 | 436.99 Mn |
| Mar 31, 2023 | 456.29 Mn |
| Dec 31, 2022 | 477.99 Mn |
| Sep 30, 2022 | 245.25 Mn |
| Jun 30, 2022 | 258.82 Mn |
| Mar 31, 2022 | 274.47 Mn |
| Dec 31, 2021 | 290.63 Mn |
| Sep 30, 2021 | 305.14 Mn |
| Jun 30, 2021 | 139.28 Mn |